TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11275030

Group type: EXPERIMENTAL
Intervention: Ginger 1 g per day for 4 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 9385881

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) for primary prevention of SCD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medications used in heart failure
Number of subjects: 0
Study: 8231601

Group type: EXPERIMENTAL
Intervention: Immunotherapy with Mycobacterium w
Number of subjects: 53

Group type: COMPARATOR
Intervention: Micronized starch as placebo (Control)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Vaccine group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 3524608

Group type: EXPERIMENTAL
Intervention: D-penicillamine (DPA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control (no DPA)
Number of subjects: 204
Study: 31625136

Group type: EXPERIMENTAL
Intervention: Autoimmune conditions (systemic lupus erythematosus, polyarteritis nodosa, autoimmune hepatitis, myasthenia gravis, uveitis)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppressive drugs used to treat autoimmune conditions
Number of subjects: 0
Study: 30002098

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 97/103 mg twice daily
Number of subjects: 414

Group type: COMPARATOR
Intervention: Irbesartan 300 mg once daily
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 414
Study: 27189162

Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs) as a continuous parameter per 10% increase
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Lymphocyte-predominant breast cancer (LPBC; ≥ 60% TILs)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs) in trastuzumab-treated subgroup
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Tumor-Infiltrating Lymphocytes (TILs) in lapatinib-treated subgroup
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: TILs as a prognostic marker for disease-free survival (DFS)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: TILs in triple-positive breast cancer
Number of subjects: 498
Study: 25304796

Group type: EXPERIMENTAL
Intervention: RA62.5 (62.5 Gy/25 fractions)
Number of subjects: 21

Group type: COMPARATOR
Intervention: RA50 (50 Gy/25 fractions)
Number of subjects: 21
Study: 22565102

Group type: EXPERIMENTAL
Intervention: CoReg approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual Care approach
Number of subjects: 20
Study: 19696764

Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention with counseling sessions
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention among completers
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention with high website utilization
Number of subjects: 101
Study: 18728130

Group type: EXPERIMENTAL
Intervention: Hot pack followed by 10‐second stretching
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Hot pack followed by 30‐second stretching
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 30‐second stretching
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10‐second stretching
Number of subjects: 29
Study: 15664721

Group type: EXPERIMENTAL
Intervention: Buprenorphine daily dosing (4, 8, 10, or 12 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine thrice weekly dosing (double maintenance dose on Monday and Wednesday, triple on Friday)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine twice weekly dosing (quadruple maintenance dose on Monday, triple on Friday)
Number of subjects: 0
Study: 11912261

Group type: EXPERIMENTAL
Intervention: AMG 073 (25 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AMG 073 (50 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AMG 073 (75 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AMG 073 (100 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AMG 073 (25 mg or 50 mg for 8 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AMG 073 (50 mg for 8 days)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AMG 073 (any dose)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 10090643

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (100 g of an amino acid mixture without tryptophan)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (100 g of an amino acid mixture with tryptophan)
Number of subjects: 27
Study: 8583092

Group type: EXPERIMENTAL
Intervention: Chili ingestion (5 g chili powder in 100 ml water)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chili instillation into the esophagus (same chili suspension)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chili ingestion
Number of subjects: 16
Study: 2347954

Group type: EXPERIMENTAL
Intervention: Dilevalol (100 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 13
Study: 895007

Group type: EXPERIMENTAL
Intervention: Gliquidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gliflumide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tolbutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 0
Study: 31375228

Group type: EXPERIMENTAL
Intervention: Fixed lingual retainer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vacuum‐formed retainer
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 45
Study: 28285645

Group type: EXPERIMENTAL
Intervention: Ma-Pi 2 diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12
Study: 25957043

Group type: EXPERIMENTAL
Intervention: Dynamically Annotated Visualizations (DAVs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Alerts
Number of subjects: 11
Study: 23151536

Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D(3)/d
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21760515

Group type: EXPERIMENTAL
Intervention: Double bending lightwand
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional bending lightwand
Number of subjects: 68
Study: 18837970

Group type: EXPERIMENTAL
Intervention: Soy drink enriched with 2.6 g plant sterol esters (1.6 g/d free plant sterol equivalents)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Soy drink without plant sterols (control)
Number of subjects: 50
Study: 17296048

Group type: EXPERIMENTAL
Intervention: Middle Level (explicitly labeled central category)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not Sure, Undecided (not explicitly labeled as central)
Number of subjects: 0
Study: 14739730

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (100 J)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (150 J)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (200 J)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Monophasic shock waveform (360 J)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (AF < 48 hours)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (AF > 48 hours)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (AF > 1 year)
Number of subjects: 203
Study: 11019933

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation treatment (general)
Number of subjects: 0
Study: 9189212

Group type: EXPERIMENTAL
Intervention: Isoniazid 300 mg daily for 6 months
Number of subjects: 684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 684
Study: 1415066

Group type: EXPERIMENTAL
Intervention: Soy-based formula
Number of subjects: 56

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 56

Group type: COMPARATOR
Intervention: Cow milk-based formula
Number of subjects: 56
Study: 4013865

Group type: EXPERIMENTAL
Intervention: Nicotine fading
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Nicotine fading/smokeholding
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 130
Study: 31469529

Group type: EXPERIMENTAL
Intervention: 100-mW diode laser at 830-nm (TINI group; n=19)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (sham group; n=19)
Number of subjects: 38
Study: 29567006

Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging
Number of subjects: 210

Group type: COMPARATOR
Intervention: Chromoendoscopy
Number of subjects: 210
Study: 26822172

Group type: EXPERIMENTAL
Intervention: 4F-Prothrombin Complex Concentrate (4F-PCC)
Number of subjects: 388

Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 388
Study: 24827132

Group type: EXPERIMENTAL
Intervention: 12-month trastuzumab treatment
Number of subjects: 261

Group type: COMPARATOR
Intervention: 6-month trastuzumab treatment
Number of subjects: 261
Study: 22488284

Group type: EXPERIMENTAL
Intervention: Heat stress (73°C) for 30 minutes
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (26°C) for 30 minutes
Number of subjects: 25
Study: 20939947

Group type: EXPERIMENTAL
Intervention: Bupivacaine-soaked sheet of regenerated oxidized cellulose positioned in the gallbladder bed
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Bupivacaine infiltrated in the muscular fasciae of the trocars' seat
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no local anesthetic)
Number of subjects: 45
Study: 16818527

Group type: EXPERIMENTAL
Intervention: Care for Development Intervention
Number of subjects: 233

Group type: COMPARATOR
Intervention: Standard health care (comparison group)
Number of subjects: 233
Study: 12624612

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg o.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Benazepril 10 mg o.d.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg plus Benazepril 10 mg o.d.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10960998

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention delivered over 12 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 38
Study: 9058296

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon-alpha + UDCA
Number of subjects: 80
Study: 8229544

Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS) 1.5 g freshly dissolved in 50 ml of water, four times daily for 3 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 2944987

Group type: EXPERIMENTAL
Intervention: Alcohol (1 ml/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31969238

Group type: EXPERIMENTAL
Intervention: Combination therapy with 0.5% podophyllotoxin solution and liquid nitrogen cryotherapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Podophyllotoxin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 110
Study: 29150922

Group type: EXPERIMENTAL
Intervention: Nasella Nose Former (NNF) in Surgical group (15 patients)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nasella Nose Former (NNF) in Cosmetic group (21 patients)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group in Surgical group (7 patients)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group in Cosmetic group
Number of subjects: 43
Study: 27246322

Group type: EXPERIMENTAL
Intervention: Brief thermal sensitization
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Heat pain detection threshold
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain during thermal stimulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain Catastrophizing Scale
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 120
Study: 25006854

Group type: EXPERIMENTAL
Intervention: Intradermal injection of PRP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chemical reconstruction of skin scars technique with TCA 100%
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Combined skin needling and PRP
Number of subjects: 45
Study: 22456343

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 42
Study: 20381724

Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 0
Study: 17507703

Group type: EXPERIMENTAL
Intervention: As-needed combination therapy (250 microg beclomethasone and 100 microg albuterol in a single inhaler as needed)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: As-needed combination therapy
Number of subjects: 455

Group type: COMPARATOR
Intervention: Regular beclomethasone therapy (250 microg twice daily)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Regular combination therapy (250 microg beclomethasone and 100 microg albuterol in a single inhaler twice daily plus 100 microg albuterol as needed)
Number of subjects: 455

Group type: COMPARATOR
Intervention: As-needed albuterol therapy (100 microg as needed)
Number of subjects: 455
Study: 16445830

Group type: EXPERIMENTAL
Intervention: AML 10 trial
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: AML 12 trial
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Combined data from AML 10 and AML 12 trials
Number of subjects: 81

Group type: COMPARATOR
Intervention: ML-DS children vs. non-DS children in trials
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: ML-DS children
Number of subjects: 81
Study: 12934465

Group type: EXPERIMENTAL
Intervention: Non-steroid anti-inflammatory drugs (NSAIDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-modifying antirheumatic drugs (DMARDs) including cyclosporin A and leflunomid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined therapy with 2 or 3 DMARDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucocorticosteroids (both small daily doses and pulse therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biological agents (monoclonal antibodies to TNF alpha and IL-4 or their receptor antagonists)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring methods for treatment safety
Number of subjects: 0
Study: 10868713

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via Respimat (RMT) 10 microg per puff, total dose 160 microg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via Respimat (RMT) 20 microg per puff, total dose 320 microg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ipratropium bromide via MDI (20 microg per puff, total dose 320 microg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide via RMT (160 microg)
Number of subjects: 36
Study: 9541999

Group type: EXPERIMENTAL
Intervention: Specialized food mixes
Number of subjects: 0
Study: 8225935

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study: 3511692

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1232

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1232

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1232
Study: 30487494

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 118

Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 118
Study: 26847379

Group type: EXPERIMENTAL
Intervention: iSTEP (SMS/MMS intervention)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 25034738

Group type: EXPERIMENTAL
Intervention: Internal drainage group
Number of subjects: 219

Group type: COMPARATOR
Intervention: External drainage group
Number of subjects: 219
Study: 22591021

Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study: 20456515

Group type: EXPERIMENTAL
Intervention: bleaching gel + halogen light (group 1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: bleaching gel (group 2)
Number of subjects: 12

Group type: COMPARATOR
Intervention: no treatment (control group 3)
Number of subjects: 12
Study: 18810400

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study: 16183129

Group type: EXPERIMENTAL
Intervention: Microincision cataract surgery (MICS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Coaxial phacoemulsification
Number of subjects: 50
Study: 12911833

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 1000-2000 micro g/day
Number of subjects: 133

Group type: COMPARATOR
Intervention: BDP/BUD >/=1750 micro g/day
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 133
Study: 10371231

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral smoking cessation program with vigorous exercise
Number of subjects: 281

Group type: COMPARATOR
Intervention: Cognitive‐behavioral smoking cessation program with equal staff contact time (control)
Number of subjects: 281
Study: 8800986

Group type: EXPERIMENTAL
Intervention: High dose intravenous dipyridamole
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (no significant coronary artery disease)
Number of subjects: 74
Study: 1799466

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b alone or in combination with chemotherapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Daily interferon
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Interferon plus low-dose hydroxyurea
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Interferon alone or combined with chemotherapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 126
Study: 6849533

Group type: EXPERIMENTAL
Intervention: EES (2 injections of epinephrine followed by Sus-Phrine)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: S (Sus-Phrine only)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: SPP (Sus-Phrine followed by 2 placebo injections)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: E (epinephrine only)
Number of subjects: 88

Group type: COMPARATOR
Intervention: EES, S, SPP (combined)
Number of subjects: 88
Study: 29157055

Group type: EXPERIMENTAL
Intervention: Haptotherapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Psycho‐education via Internet
Number of subjects: 134

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 134
Study: 28055065

Group type: EXPERIMENTAL
Intervention: Fish oil (4 g/d)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 567
Study: 26094361

Group type: EXPERIMENTAL
Intervention: Orthodontic toothbrush
Number of subjects: 26

Group type: COMPARATOR
Intervention: Triple-headed toothbrush
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combined brushing with single-tufted toothbrush
Number of subjects: 26
Study: 23931935

Group type: EXPERIMENTAL
Intervention: 200 mU abobotulinumtoxinA
Number of subjects: 8

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 8
Study: 21574032

Group type: EXPERIMENTAL
Intervention: Swaddling
Number of subjects: 85
Study: 19739698

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Suboxone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less frequent dispensing of buprenorphine/naloxone (thrice weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone
Number of subjects: 0
Study: 16328475

Group type: EXPERIMENTAL
Intervention: Ambu laryngeal mask (ALM)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LMA‐Classic (LMA)
Number of subjects: 60
Study: 14687691

Group type: EXPERIMENTAL
Intervention: Immucytal (one tablet daily in the morning for 8 days per month for three consecutive months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (one tablet daily in the morning for 8 days per month for three consecutive months)
Number of subjects: 72
Study: 12212256

Group type: EXPERIMENTAL
Intervention: Traditional chordal reconstruction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Chordal replacement using expanded polytetrafluorethylene (e‐PTFE) sutures and artificial ring valvuloplasty reconstruction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 57
Study: 9070549

Group type: EXPERIMENTAL
Intervention: saruplase (80 mg/hour, n = 236)
Number of subjects: 473

Group type: COMPARATOR
Intervention: alteplase (100 mg every 3 hours, n = 237)
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: saruplase
Number of subjects: 473

Group type: COMPARATOR
Intervention: alteplase
Number of subjects: 473

Group type: EXPERIMENTAL
Intervention: saruplase and alteplase
Number of subjects: 473
Study: 8438616

Group type: EXPERIMENTAL
Intervention: Single dose of 2 x 10(9) live bacteria
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Three doses every other day of 2 x 10(9) live bacteria
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Booster dose of 2 x 10(9) live bacteria after 6 months
Number of subjects: 30
Study: 3025928

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (a competitive opiate receptor antagonist)
Number of subjects: 12
Study: 30132108

Group type: EXPERIMENTAL
Intervention: Low-speed centrifugation (800 r/min)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sedimentation (15 min)
Number of subjects: 100
Study: 28797829

Group type: EXPERIMENTAL
Intervention: 12-week internet intervention (Deprexis) plus usual care
Number of subjects: 1013

Group type: COMPARATOR
Intervention: Care as usual alone
Number of subjects: 1013
Study: 26637080

Group type: EXPERIMENTAL
Intervention: Early postoperative feeding (oral clear fluids began up to six hours after surgery followed by solid foods as tolerated)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Delayed postoperative feeding (clear fluids began on the first postoperative day and solid foods on the second or third day as tolerated)
Number of subjects: 119